Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
McLornan DP, Malpassuti V, Lippinkhof-Kozijn A, Potter V, Beelen D, Bunjes D, Sengeloev H, Radujkovic A, Passweg J, Chalandon Y, Kröger N, Wulf GG, Johansson JE, Ciceri F, Bornhäuser M, Holler E, Guffroy B, Martin S, Neubauer A, Gramatski M, Robin M, Iacobelli S, Hayden P, Hernández Boluda JC, Czerw T, Yakoub-Agha I. McLornan DP, et al. Among authors: bunjes d. Br J Haematol. 2020 Aug;190(3):437-441. doi: 10.1111/bjh.16537. Epub 2020 Feb 28. Br J Haematol. 2020. PMID: 32108327 Free article.
Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia.
Hebart H, Löffler J, Reitze H, Engel A, Schumacher U, Klingebiel T, Bader P, Böhme A, Martin H, Bunjes D, Kern WV, Kanz L, Einsele H. Hebart H, et al. Among authors: bunjes d. Br J Haematol. 2000 Nov;111(2):635-40. doi: 10.1046/j.1365-2141.2000.02378.x. Br J Haematol. 2000. PMID: 11122112 Free article.
CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients.
Ringhoffer M, Wiesneth M, Harsdorf S, Schlenk RF, Schmitt A, Reinhardt PP, Moessner M, Grimminger W, Mertens T, Reske SN, Döhner H, Bunjes D. Ringhoffer M, et al. Among authors: bunjes d. Br J Haematol. 2004 Aug;126(4):527-35. doi: 10.1111/j.1365-2141.2004.05062.x. Br J Haematol. 2004. PMID: 15287946 Free article.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: bunjes d. Blood. 2005 Jul 15;106(2):458-63. doi: 10.1182/blood-2004-05-1746. Epub 2005 Apr 7. Blood. 2005. PMID: 15817679 Free article. Clinical Trial.
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D. Ringhoffer M, et al. Among authors: bunjes d. Br J Haematol. 2005 Aug;130(4):604-13. doi: 10.1111/j.1365-2141.2005.05663.x. Br J Haematol. 2005. PMID: 16098076 Free article. Clinical Trial.
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T. Hess G, et al. Among authors: bunjes d. J Clin Oncol. 2005 Oct 20;23(30):7583-93. doi: 10.1200/JCO.2005.01.3110. J Clin Oncol. 2005. PMID: 16234522 Clinical Trial.
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Ringhoffer M, Harsdorf Sv, Schmitt M, Wiesneth M, Zenz T, Stilgenbauer S, Greiner J, Döhner K, Marx M, Döhner H, Bunjes D. Ringhoffer M, et al. Among authors: bunjes d. Br J Haematol. 2007 Jan;136(1):127-30. doi: 10.1111/j.1365-2141.2006.06404.x. Br J Haematol. 2007. PMID: 17222200 Free article. Clinical Trial.
226 results